Cipher's Two-Pronged Strategy: Epuris Expansion and Natroba Commercial Diversification

Q2 2026 reveals a company actively managing Medicaid pressures on its U.S. brand while accelerating Canadian growth through public drug plan access and a sharper M&A focus.

CPH.TO · Earnings Call · 2026-08-12

Natroba: Weathering Medicaid Headwinds

Cipher's second quarter of 2026 highlighted the fragility of its U.S. Natroba franchise, which saw revenue fall to $6.3 million from $7.8 million a year earlier. Management attributed the decline squarely to reduced sales volumes from state Medicaid programs, a channel that had been a historical strength. As CEO Craig Mull put it, “In the quarter, the U.S.-based Natroba business experienced pressure with respect to sales volumes.” — Craig Mull, CEO · 2026-08-12 The pressure is rooted in market dynamics beyond the company's control, but the response is decidedly proactive. President of U.S. Business Bryan Jacobs detailed investments in a first-in-class direct-to-patient platform and a landmark retail agreement: “We're happy to announce that we closed one of them to make Natroba and Spinosad available at every single Walmart across the U.S.” — Bryan Jacobs, President, U.S. Business · 2026-08-12 These moves target commercial payer volumes—a deliberate shift to diversify beyond Medicaid. The company's earlier pivot toward DTC, discussed on the November 2025 call, is now materializing: “We're going to launch this, and we believe it's going to be kind of the next phase of growth for the Natroba franchise.” — Bryan Jacobs, Senior Executive · 2025-11-07 While the quarter's lower revenue is a setback, the strategic emphasis on retail and direct channels suggests management is building a more resilient commercial infrastructure.

Epuris: Unlocking Public Markets

In contrast, the Canadian portfolio continues to shine. Epuris revenue grew 14% to $4.1 million, with volumes up 8% and market share reaching 47.1%. The most significant catalyst came with the signing of a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA) to expand public drug plan coverage. This is a breakthrough after years of limited success in key provinces. Mull highlighted its importance:

The public drug plan coverage is something we have been pursuing in key markets with limited success for some time. Therefore, the signing of the letter of intent with the pCPA is an exciting achievement for Cipher and Epuris, and truly beneficial to the Canadian patient population navigating severe nodular acne.
Craig Mull, CEO · 2026-08-12

The expansion is expected to broaden patient access and significantly enlarge Epuris's addressable market, particularly in regions where public plans dominate. Management anticipates finalizing listing agreements over the next 30–60 days, which could drive meaningful market share gains. This development is a clear departure from prior quarters—the keyword public drug plan now carries the company's highest momentum, a signal that this strategic pivot is fresh and central.

Business Development: Patience and Discipline

Cipher remains highly active in M&A and licensing, but the quarter also demonstrated discipline. The company revealed it walked away from a large acquisition target after due diligence, citing product and pricing concerns. As Mull noted, “as many things, a combination of concerns about some products and price meant that at this point in time, at this date, that it's probably not the right deal for Cipher.” — Craig Mull, CEO · 2026-08-12 This contrasts with earlier optimism, but the pipeline remains robust. The company continues to pursue in-licensing opportunities that fit its existing commercial infrastructure, as well as out-licensing for Epuris and Natroba globally. The strategic focus on acquisition of products and companies is unchanged, but the bar for execution is higher. Financially, the company maintains a fortress balance sheet: debt-free with $9.1 million in cash and $90 million in available financing. Adjusted EBITDA margin held at 57% for the quarter and 59% year-to-date, underscoring that profitability remains intact despite top-line pressure. As CFO Ryan Mailling summarized, “Total net revenue for the three and six months ended June 30th, 2026 was $12.1 million and $24.6 million respectively.” — Ryan Mailling, CFO · 2026-08-12 The revenue dip is real, but the underlying earnings power and cash generation are proving resilient.